Veteran scientist Hideo Makimura, M.D., Ph.D., is going fully preclinical by joining gene therapy biotech Affinia Therapeutics as chief medical officer. Makimura most recently served in leadership ...

Daiichi Sankyo promoted Hiroyuki Okuzawa as CEO, succeeding Sunao Manabe, DVM, PhD on April 1, 2025. Astellas’ chief commercial officer Claus Zieler is set to take up the new role of chief commercial ...

Daiichi Sankyo announced that Hiroyuki Okuzawa will serve as its new CEO starting on April 1, 2025. 1 The previous CEO, Sunao Manabe, DVM, PhD, will continue to serve as representative director and ...

Tokyo: Daiichi Sankyo Company, Ltd has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO), effective April 1, 2025. Dr. Manabe will transition from ...

30 January 2025 New US President Donald Trump and his administration have confirmed that lowering the cost of prescription drugs for Americans is a top priority, suggesting that they will continue the ...

Daiichi Sankyo Company, , an innovative global healthcare company, has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as chief executive officer (CEO), effective April 1, 2025. Dr ...

Japanese drugmaker Daiichi Sankyo (TYO: 4568) has appointed Hiroyuki Okuzawa to succeed Sunao Manabe, as chief executive (CEO), effective April 1, 2025. Dr Manabe will transition from his current role ...

Manabe began her career in molecular biology research. When she graduated from Columbia University College of Physicians and Surgeons in 1991, the majority of the internal medicine patients had HIV or ...

Daiichi Sankyo has announced that Hiroyuki Okuzawa will succeed Sunao Manabe as its CEO from 1 April 2025. The company's board of directors followed the nomination committee's report, appointing ...